Executive Management

Matthew Rabinowitz, Ph.D. is a co-founder of our company and currently serves as our Executive Chairman. Dr. Rabinowitz served as our Chief Executive Officer from 2005 to January 2019, and served as a member of our board of directors since 2005. He served as Chairman of our board of directors from May 2015 to January 2019, at which time he assumed the role of Executive Chairman. Prior to co-founding our company, Dr. Rabinowitz served from 2000 to 2003 as chief executive officer and from 2003 to 2007 as chief technology officer of Rosum Corporation, a location services technology company. Dr. Rabinowitz served as a consulting professor at Stanford University from 2004 to 2012 and as visiting faculty in the Genetics Department of Harvard University from 2018 to 2019. Dr. Rabinowitz has over 100 patents and publications in signal processing, machine learning, bio-informatics, and high-throughput genetic testing. He received the Scott Helt Memorial Award from the Institute of Electrical and Electronics Engineers and has twice received the Technology Pioneer Award from the World Economic Forum. He currently serves as a member of the board of directors or advisory board of a number of technology companies. Dr. Rabinowitz holds a Bachelor of Science degree in Engineering and Physics, a Master of Science in Electrical Engineering, and a Ph.D. in Electrical Engineering, from Stanford University.

Steve Chapman is Natera’s Chief Executive Officer and serves on the company’s board of directors. During his tenure, he has held a number of leadership roles including Chief Operating Officer. As COO, he led the company’s entry into the highly competitive non-invasive prenatal testing market, in which the company’s Panorama® test became the market leader despite being fourth to market. Mr. Chapman was appointed CEO in January 2019 and has been instrumental in extending Natera’s core technology to address new organ health and oncology markets. This includes driving rapid growth for the Prospera™ transplant assessment test, launching the RenasightTM test which screens for genetic causes of chronic kidney disease, and establishing Natera’s leadership in molecular residual disease testing with Signatera.™ Since becoming CEO, Natera has achieved significant year-on-year revenue growth and has consistently outperformed earnings expectations. Prior to joining Natera, Mr. Chapman worked at Genzyme Genetics, where he was credited with delivering record-breaking growth and strategies that changed pregnancy genetic testing. Mr. Chapman began his career as a researcher in the department of human genetics at UCLA designing arrays identifying SNPs associated with multiple sclerosis. He graduated with honors and holds a B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA.

Robert Schueren is an accomplished industry veteran with extensive molecular diagnostics, genomics, and pharma experience. Mr. Schueren has enjoyed an expansive 30-year career and has been a driving force behind rapid business growth at both start-up and large biotech companies. Most recently, he was CEO of IntegenX Inc., playing a critical role in the growth and success of the company, and ultimate acquisition by Thermo Fisher Scientific, as well as successfully leading a lobbying effort to pass the Rapid DNA Act of 2017. Mr. Schueren previously held executive leadership roles including GM of Genomics at Agilent Technologies, Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc. He formerly held leadership and commercial roles at Arcturus Bioscience, Accumetrics, Biosite Diagnostics, Gen-Probe, and Abbott Labs. Mr. Schueren received a BS in Pharmacy from Temple University.

Mike Brophy is Natera’s CFO. He joined Natera in 2015 serving as Natera’s Senior Vice President of Finance and Investor Relations, and prior to that as Vice President of Corporate Development and Investor Relations. Prior to joining Natera, he served as an executive director and as a vice president in the investment banking division of Morgan Stanley, where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds a master’s degree in business administration from the University of California, Los Angeles, and a Bachelor of Science degree in economics from the United States Air Force Academy. His military career included leading a multi-agency, 10-person team on a $1.4 billion contract to modernize 10 remote satellite tracking stations worldwide.

Daniel Rabinowitz is Secretary and Chief Legal Officer of Natera. Prior to joining Natera, he was a corporate partner at the law firm McDermott, Will & Emery, and, before that, was also a corporate lawyer at the law firm Davis Polk & Wardwell. He has worked in the United States and Europe advising domestic, foreign, public, and private companies on capital raisings, M&A, investment management and compliance with US federal and state securities law. He has studied genetics, biochemistry, and molecular biology at Harvard University Extension School and attended courses on the legal and ethical aspects of biotechnology at Harvard Law School. Mr. Rabinowitz completed his BA and LLB degrees at the University of the Witwatersrand, South Africa, graduating at the top of his law school class, and completed his LLM at New York University School of Law with both Rotary Foundation and Fulbright Scholarships. Admitted in New York only.